Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical trial update and novel therapeutic approaches for metastatic prostate cancer.

Larsson R, Mongan NP, Johansson M, Shcherbina L, Abrahamsson PA, Gudas LJ, Sterner O, Persson JL.

Curr Med Chem. 2011;18(29):4440-53. Review.

PMID:
21864277
2.

Androgen receptor antagonists for prostate cancer therapy.

Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F.

Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 Mar 17. Review.

PMID:
24639562
3.

Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.

Lakshmana G, Baniahmad A.

Int J Cancer. 2019 Apr 15;144(8):1775-1779. doi: 10.1002/ijc.31818. Epub 2018 Nov 4. Review.

PMID:
30125354
4.

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C.

J Biol Chem. 2013 Jul 5;288(27):19359-69. doi: 10.1074/jbc.M113.477216. Epub 2013 May 16.

5.

Androgen action in the prostate gland.

Yadav N, Heemers HV.

Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Review.

PMID:
22402316
7.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

8.

Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.

Oncotarget. 2017 Jan 10;8(2):3724-3745. doi: 10.18632/oncotarget.12554. Review.

9.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.

Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.

PMID:
28851578
10.

A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.

Hessenkemper W, Roediger J, Bartsch S, Houtsmuller AB, van Royen ME, Petersen I, Grimm MO, Baniahmad A.

Mol Endocrinol. 2014 Nov;28(11):1831-40. doi: 10.1210/me.2014-1170. Epub 2014 Sep 9.

11.

Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.

Biron E, B├ędard F.

J Steroid Biochem Mol Biol. 2016 Jul;161:36-44. doi: 10.1016/j.jsbmb.2015.07.006. Epub 2015 Jul 18. Review.

12.

Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.

13.

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Antonarakis ES, Armstrong AJ, Dehm SM, Luo J.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):231-41. doi: 10.1038/pcan.2016.17. Epub 2016 May 17. Review.

14.

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.

Semenas J, Dizeyi N, Persson JL.

Drug Des Devel Ther. 2013 Aug 27;7:875-81. doi: 10.2147/DDDT.S45703. eCollection 2013. Review.

15.

Targeting continued androgen receptor signaling in prostate cancer.

Massard C, Fizazi K.

Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815. Review.

16.

TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.

Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, Takahashi S, Homma Y, Ouchi Y, Inoue S.

Mol Endocrinol. 2012 May;26(5):748-61. doi: 10.1210/me.2011-1242. Epub 2012 Mar 28.

17.

Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Penning TM.

J Steroid Biochem Mol Biol. 2015 Sep;153:105-13. doi: 10.1016/j.jsbmb.2015.05.010. Epub 2015 May 29. Review.

18.

Androgen action and metabolism in prostate cancer.

Green SM, Mostaghel EA, Nelson PS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13. doi: 10.1016/j.mce.2011.09.046. Epub 2012 Mar 20. Review.

19.

Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.

Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C.

Mol Carcinog. 2016 Dec;55(12):2278-2290. doi: 10.1002/mc.22468. Epub 2016 Feb 19.

PMID:
26894509
20.

The transcriptional programme of the androgen receptor (AR) in prostate cancer.

Lamb AD, Massie CE, Neal DE.

BJU Int. 2014 Mar;113(3):358-66. doi: 10.1111/bju.12415. Review.

Supplemental Content

Support Center